Search Results for “cancer” – Page 49 – media

Multiple sclerosis drug could reduce painful side effects of common cancer treatment

Researchers from the Saint Louis University School of Medicine have discovered why many multiple myeloma patients experience severe pain when treated with the anticancer drug bortezomib. The study, which will be published April 27 in the Journal of Experimental Medicine, suggests that a drug already approved to treat multiple sclerosis could mitigate this effect, allowing myeloma patients to successfully complete their treatment and relieving the pain of myeloma survivors.
- Source: medicalxpress.
- 454
- April 28, 2018
multiple myeloma Researches
Hanmi Pharma gives up on development of lung cancer drug Olita

South Korean pharmaceutical firm Hanmi Pharmaceutical is expected to cease development of Olita, a lung cancer treatment, following its slow progress in clinical trials and cancellation of licensing deals with foreign drug makers.
- Source: koreaher
- 2,356
- April 20, 2018
Clinical Trials Company Insights Olita
XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer

XBiotech USA, Inc. (NASDAQ:XBIT) announced today that it has obtained an exclusive, worldwide license from CT Atlantic AG (CTA), a Swiss biotechnology company. Under the terms of the license agreement, XBiotech will use its proprietary manufacturing technology to advance the development of the True HumanTM anti-NY-ESO-1 monoclonal antibody, 12D7.
- Source: Forextv
- 877
- April 18, 2018
12D7 antibody Market Views
Updated Overall Survival Data for LYNPARZA® (olaparib) in gBRCA-Mutated HER2-Negative Metastatic Breast Cancer Presented at AACR

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today presented data from the Phase III OlympiAD trial, showing the final overall survival (OS) results for LYNPARZA®(olaparib) in metastatic breast cancer at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, April 14-18, 2018.
- Source: businesswire
- 863
- April 17, 2018
AstraZeneca breast cancer Clinical Trials Merk
Portable Cancer-Detecting Device Being Developed By Korean Startup

To diagnose cancer, doctors use a bunch of complex examinations like an MRI, a CT scan, a biopsy or a lengthy blood test. Because of the sophisticated machines and equipment needed for these techniques and procedures, they are only conducted in the hospital setting. One startup is about to change this with its portable cancer-detecting device.
- Source: International Business Times
- 1,950
- April 13, 2018
cancer medical device Researches
Illumina and Loxo Oncology to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics

Illumina, Inc. (Nasdaq: ILMN) and Loxo Oncology (Nasdaq: LOXO) today announced a global strategic partnership to develop and commercialize a multi-gene panel for broad tumor profiling, resulting in a distributable, next-generation sequencing (NGS) based companion diagnostic (CDx) with a pan-cancer indication.
- Source: Illumina
- 497
- April 12, 2018
larotrectinib Market Views
FDA Approves Rucaparib for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

On April 6, 2018, the Food and Drug Administration(FDA) approved rucaparib (Rubraca®, Clovis Oncology Inc.), a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
- Source: asco.org
- 532
- April 11, 2018
FDA New Approvals rucaparib
U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) in Previously Treated dMMR or MSI-H Metastatic Colorectal Cancer

Application based on results from Phase 2 CheckMate -142 study
- Source: investors.bms
- 606
- April 11, 2018
Bristol-Myers Squibb FDA New Approvals Opdivo
Sanofi’s PD-1 inhibitor starts EU review for skin cancer

The EMA has kicked off its review of Sanofi and Regeneron’s immuno-oncology drug cemiplimab, which is aiming to become the sixth drug in the PD-1/PD-L1 inhibitor class to reach the market.
- Source: Pmlive
- 549
- April 8, 2018
cemiplimab immuno-oncology New Approvals
Singapore’s Aslan stalks $86M IPO to fund cancer pipeline

Aslan wants to list on the U.S. exchange under the ASLN symbol.
- Source: fiercebiotech
- 541
- April 5, 2018
Aslan Market Views varlitinib

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.